Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2025
|
| Online Access: | https://doi.org/10.5281/zenodo.17355383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p><strong>Background: </strong>Children are at high risk of desaturation during anesthesia induction due to limited oxygen reserves. Traditional face mask preoxygenation is effective but often poorly tolerated. High-flow nasal cannula (HFNC) offers continuous oxygen delivery, low-level positive pressure, and improved comfort, potentially enhancing oxygenation stability.</p> <p><strong>Objective: </strong>To compare SpO₂ stability between HFNC and face mask during pediatric preoxygenation.</p> <p><strong>Methods: </strong>A prospective case–control study was conducted at Yadgir Institute of Medical Sciences (April–August 2025), including 50 children (2–12 years, ASA I–II) undergoing elective surgery. Patients were assigned to HFNC (Group A, n=25) or face mask (Group B, n=25) preoxygenation with FiO₂ 1.0 for 3 minutes. SpO₂ at baseline, during preoxygenation, induction, and post-intubation was recorded, along with desaturation events (SpO₂ <94%), safe apnea time, recovery time, hemodynamic stability, and device tolerance.</p> <p><strong>Results: </strong>Both groups were demographically comparable. HFNC achieved significantly higher SpO₂ after 1–3 minutes of preoxygenation (p<0.01) and during induction/post-intubation (p<0.01). Desaturation was less frequent with HFNC (4% vs 24%, p=0.04), with longer safe apnea time (180±20 vs 120±25 sec, p<0.001) and faster recovery (15±6 vs 28±10 sec, p=0.002). HFNC scored higher for patient comfort (4.7±0.4 vs 3.9±0.7, p<0.001). Hemodynamic responses were similar between groups.</p> <p><strong>Conclusion: </strong>HFNC provides superior SpO₂ stability, fewer desaturation episodes, and better tolerance compared to face mask preoxygenation in children. It represents a safe and effective alternative in pediatric anesthesia, warranting confirmation in larger multicenter trials.</p>